* Ventyx Biosciences Inc VTYX.OQ reported a quarterly
adjusted
loss of 62 cents per share for the quarter ended in March,
higher than the same quarter last year, when the company
reported EPS of -68 cents. The mean expectation of
eight analysts for the quarter was for a loss of 69 cents per
share. Wall Street expected results to range from -86 cents
to -38 cents per share.
* Reported revenue was zero; analysts expected zero.
* Ventyx Biosciences Inc's reported EPS for the quarter was
a loss
of 62 cents.
* The company reported a quarterly loss of $38.57 million.
* Ventyx Biosciences Inc shares had fallen by 19.3% this
quarter and gained 79.8% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 20.8%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Ventyx
Biosciences Inc is $9.50
This summary was machine generated from LSEG data May 9 at 09:01
p.m. UTC. All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.69 -0.62 Beat
Dec. 31 2023 -0.90 -0.79 Beat
Sep. 30 2023 -0.90 -0.92 Missed
Jun. 30 2023 -0.71 -0.91 Missed